Piramal Pharma Ltd
NSE:PPLPHARMA
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
115.5
293.55
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Gross Margin
Piramal Pharma Ltd
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | IN |
| Market Cap | 328.9B INR |
| Gross Margin |
64%
|
| Country | JP |
| Market Cap | 776 550.9T JPY |
| Gross Margin |
-3%
|
| Country | US |
| Market Cap | 749.7B USD |
| Gross Margin |
81%
|
| Country | UK |
| Market Cap | 440.4B GBP |
| Gross Margin |
56%
|
| Country | DK |
| Market Cap | 3.4T DKK |
| Gross Margin |
85%
|
| Country | US |
| Market Cap | 372B USD |
| Gross Margin |
69%
|
| Country | US |
| Market Cap | 257.3B USD |
| Gross Margin |
77%
|
| Country | CH |
| Market Cap | 200.4B CHF |
| Gross Margin |
73%
|
| Country | UK |
| Market Cap | 162.7B GBP |
| Gross Margin |
82%
|
| Country | CH |
| Market Cap | 179.9B CHF |
| Gross Margin |
75%
|
| Country | IE |
| Market Cap | 146B USD |
| Gross Margin |
68%
|
Piramal Pharma Ltd
Glance View
Piramal Pharma Ltd. engages in development and manufacturing of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 0 full-time employees. The company went IPO on 2022-10-19. The firm has approximately 15 global facilities and a global distribution network in over 100 countries. The firm's subsidiaries include Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business, and the India consumer healthcare business selling over-the-counter products. PPS offers end-to-end development and manufacturing solutions through a globally integrated network of facilities across the drug life cycle to generic companies. PCC's complex hospital product portfolio includes inhalation anesthetics, intrathecal therapies for spasticity and pain management, injectable pain and anesthetics, injectable anti-infectives, and other therapies.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Piramal Pharma Ltd's most recent financial statements, the company has Gross Margin of 63.7%.
You don't have any saved screeners yet
